prochlorperazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2274	58-38-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prochlorperazine mesylate prochlorperazine capazine chlormeprazine chlorperazine meterazin meterazine proazine prochlorpemazine prochlorperazin prochlorpromazine prochlorperazine maleate prochlorperazine edisylate prochlorperazine dimaleate prochlorperzine	A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Molecular weight: 373.94 Formula: C20H24ClN3S CLOGP: 4.58 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 9.72 ALOGS: -4.53 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prochlorperazine mesylate
prochlorperazine
capazine
chlormeprazine
chlorperazine
meterazin
meterazine
proazine
prochlorpemazine
prochlorperazin
prochlorpromazine
prochlorperazine maleate
prochlorperazine edisylate
prochlorperazine dimaleate
prochlorperzine

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Molecular weight: 373.94
Formula: C20H24ClN3S
CLOGP: 4.58
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 9.72
ALOGS: -4.53
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
50	mg	P
0.10	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	22 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 23, 1956	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nausea	353.75	11.64	1549	49912	754542	52543063
Febrile neutropenia	320.78	11.64	448	51013	104488	53193117
Drug ineffective	270.69	11.64	236	51225	817009	52480596
Disease progression	257.71	11.64	398	51063	101522	53196083
Dehydration	217.82	11.64	493	50968	167917	53129688
Diarrhoea	198.68	11.64	1151	50310	624395	52673210
White blood cell count decreased	198.58	11.64	397	51064	124078	53173527
Vomiting	193.81	11.64	968	50493	496171	52801434
Plasma cell myeloma	156.02	11.64	211	51250	47663	53249942
Platelet count decreased	136.85	11.64	314	51147	107785	53189820
Fatigue	135.78	11.64	1181	50280	729325	52568280
Rheumatoid arthritis	124.09	11.64	75	51386	314456	52983149
Contraindicated product administered	116.66	11.64	3	51458	135626	53161979
Neutropenia	113.86	11.64	375	51086	158810	53138795
Death	108.65	11.64	651	50810	356581	52941024
Constipation	102.00	11.64	420	51041	197992	53099613
Malignant neoplasm progression	99.68	11.64	216	51245	71325	53226280
Systemic lupus erythematosus	91.37	11.64	8	51453	125406	53172199
Synovitis	90.53	11.64	3	51458	107890	53189715
Asthenia	87.65	11.64	599	50862	342991	52954614
Toxicity to various agents	87.04	11.64	52	51409	219546	53078059
Arthropathy	86.30	11.64	16	51445	141437	53156168
Blood magnesium decreased	75.87	11.64	74	51387	11740	53285865
Decreased appetite	75.21	11.64	407	51054	214567	53083038
Therapeutic product effect decreased	74.98	11.64	15	51446	125640	53171965
Neutrophil count decreased	73.89	11.64	153	51308	48945	53248660
Joint swelling	73.26	11.64	71	51390	234567	53063038
Full blood count decreased	69.43	11.64	100	51361	23929	53273676
Neuropathy peripheral	66.60	11.64	235	51226	102952	53194653
Heart rate abnormal	64.54	11.64	43	51418	3957	53293648
Hospice care	62.68	11.64	50	51411	6080	53291525
Pleural effusion	61.75	11.64	207	51254	88372	53209233
Akathisia	61.34	11.64	57	51404	8514	53289091
Carbohydrate antigen 125 increased	60.18	11.64	35	51426	2533	53295072
Thrombosis	59.34	11.64	160	51301	60633	53236972
Abdominal pain	58.66	11.64	435	51026	255468	53042137
Neoplasm progression	58.24	11.64	104	51357	29815	53267790
Glossodynia	57.72	11.64	13	51448	100278	53197327
Lymphadenitis	54.99	11.64	34	51427	2751	53294854
Therapeutic product effect incomplete	54.65	11.64	11	51450	91773	53205832
Condition aggravated	53.29	11.64	131	51330	297003	53000602
Clostridium difficile infection	50.54	11.64	94	51367	27799	53269806
Small intestinal obstruction	50.47	11.64	72	51389	17075	53280530
Gangrene	48.20	11.64	39	51422	4838	53292767
Completed suicide	47.71	11.64	38	51423	138163	53159442
Pericarditis	47.19	11.64	4	51457	64402	53233203
Arterial occlusive disease	44.95	11.64	38	51423	5011	53292594
Thrombocytopenia	43.38	11.64	255	51206	138472	53159133
Pancytopenia	43.14	11.64	188	51273	90740	53206865
Neovascularisation	43.14	11.64	18	51443	629	53296976
Injection site erythema	42.51	11.64	11	51450	77238	53220367
Coma	42.24	11.64	5	51456	61778	53235827
Colitis	42.20	11.64	111	51350	41441	53256164
Injection site pain	40.63	11.64	30	51431	113361	53184244
Treatment failure	39.86	11.64	39	51422	128364	53169241
Red blood cell count decreased	39.66	11.64	99	51362	35804	53261801
Maternal exposure during pregnancy	38.99	11.64	56	51405	155583	53142022
Palmar-plantar erythrodysaesthesia syndrome	38.13	11.64	72	51389	21534	53276071
Cytokine release syndrome	38.03	11.64	43	51418	8086	53289519
Failure to thrive	37.96	11.64	40	51421	6952	53290653
General physical health deterioration	37.68	11.64	52	51409	146890	53150715
Pneumonitis	37.13	11.64	88	51373	30800	53266805
Swelling	36.84	11.64	81	51380	191024	53106581
Pain	35.46	11.64	380	51081	588018	52709587
Infusion related reaction	35.37	11.64	60	51401	155897	53141708
Intentional overdose	34.34	11.64	11	51450	67194	53230411
Weight decreased	34.34	11.64	362	51099	234586	53063019
Psoriasis	33.93	11.64	21	51440	87068	53210537
Alopecia areata	33.67	11.64	20	51441	1505	53296100
Blood creatine increased	33.62	11.64	32	51429	4925	53292680
Pneumonia	32.41	11.64	562	50899	406607	52890998
Hair texture abnormal	31.71	11.64	28	51433	3914	53293691
Lower respiratory tract infection	31.41	11.64	25	51436	90956	53206649
Drug intolerance	31.29	11.64	98	51363	205395	53092210
Injection site reaction	30.73	11.64	6	51455	51160	53246445
Hair colour changes	30.62	11.64	24	51437	2845	53294760
Rectal cancer metastatic	30.48	11.64	11	51450	258	53297347
Off label use	30.45	11.64	300	51161	471912	52825693
Psoriatic arthropathy	30.35	11.64	5	51456	48185	53249420
Hepatic enzyme increased	30.06	11.64	47	51414	126148	53171457
Drug hypersensitivity	30.01	11.64	389	51072	264853	53032752
Haemoglobin decreased	28.92	11.64	229	51232	137078	53160527
Anaemia	28.90	11.64	400	51061	276318	53021287
Taste disorder	28.84	11.64	37	51424	7931	53289674
Blood potassium decreased	27.69	11.64	94	51367	40366	53257239
Wound	27.06	11.64	29	51432	91528	53206077
Muscle twitching	26.85	11.64	53	51408	16373	53281232
Hypokalaemia	26.74	11.64	172	51289	96345	53201260
Hypophagia	26.61	11.64	78	51383	30984	53266621
Mucosal inflammation	26.34	11.64	96	51365	42688	53254917
Mobility decreased	26.27	11.64	21	51440	76250	53221355
Sepsis	25.97	11.64	235	51226	146194	53151411
Overdose	24.83	11.64	41	51420	107695	53189910
Dysgeusia	24.49	11.64	94	51367	42837	53254768
Back pain	24.19	11.64	338	51123	233909	53063696
Drug interaction	24.18	11.64	119	51342	219210	53078395
Suicide attempt	24.12	11.64	13	51448	58155	53239450
Asthma	23.72	11.64	43	51418	108929	53188676
Injection site swelling	23.58	11.64	6	51455	42622	53254983
Oral pain	23.58	11.64	68	51393	26769	53270836
Hyponatraemia	23.34	11.64	182	51279	108425	53189180
Gastric disorder	23.26	11.64	73	51388	30092	53267513
Knee arthroplasty	22.25	11.64	3	51458	33566	53264039
Lymphadenopathy	22.03	11.64	81	51380	36174	53261431
Dry skin	21.98	11.64	95	51366	45665	53251940
Cholestasis of pregnancy	21.96	11.64	14	51447	1195	53296410
Exposure during pregnancy	21.60	11.64	56	51405	124804	53172801
Weight increased	21.40	11.64	113	51348	204454	53093151
Red cell distribution width increased	21.22	11.64	34	51427	8926	53288679
Autoimmune nephritis	20.96	11.64	9	51452	338	53297267
Folliculitis	20.63	11.64	3	51458	31706	53265899
C-reactive protein increased	20.62	11.64	21	51440	67865	53229740
Hypoxia	20.49	11.64	107	51354	55573	53242032
Tumour marker increased	20.37	11.64	22	51439	3931	53293674
Pyrexia	20.12	11.64	520	50941	402673	52894932
Musculoskeletal stiffness	20.08	11.64	57	51404	123311	53174294
Discomfort	19.61	11.64	39	51422	95433	53202172
Deep vein thrombosis	19.53	11.64	142	51319	82771	53214834
Skull fracture	19.38	11.64	12	51449	973	53296632
Irritable bowel syndrome	19.22	11.64	9	51452	43623	53253982
Plasma cell myeloma recurrent	19.08	11.64	18	51443	2739	53294866
Madarosis	18.68	11.64	18	51443	2812	53294793
Abortion spontaneous	18.50	11.64	11	51450	46624	53250981
Skin exfoliation	18.17	11.64	76	51385	36007	53261598
Coronary artery disease	17.94	11.64	5	51456	33432	53264173
Laboratory test abnormal	17.85	11.64	58	51403	24351	53273254
Loss of personal independence in daily activities	17.59	11.64	25	51436	69790	53227815
Acquired cystic kidney disease	17.52	11.64	5	51456	53	53297552
Red blood cell sedimentation rate increased	17.47	11.64	3	51458	28054	53269551
Mental status changes	17.39	11.64	80	51381	39491	53258114
Parkinsonism	17.11	11.64	31	51430	8982	53288623
Hypermagnesaemia	16.69	11.64	11	51450	994	53296611
Fibromyalgia	16.65	11.64	11	51450	44064	53253541
Arthralgia	16.48	11.64	312	51149	439471	52858134
Paradoxical drug reaction	16.26	11.64	18	51443	3307	53294298
Injection site pruritus	16.23	11.64	10	51451	41579	53256026
Injection site bruising	16.22	11.64	8	51453	37638	53259967
Morbid thoughts	16.08	11.64	9	51452	605	53297000
Drug reaction with eosinophilia and systemic symptoms	15.67	11.64	6	51455	32794	53264811
Pancreatic carcinoma recurrent	15.58	11.64	5	51456	81	53297524
Nasopharyngitis	15.56	11.64	115	51346	192180	53105425
Clostridium difficile colitis	15.39	11.64	48	51413	19717	53277888
Ill-defined disorder	15.35	11.64	15	51446	49429	53248176
Ovarian cancer recurrent	15.24	11.64	11	51450	1152	53296453
Pulmonary embolism	15.15	11.64	173	51288	114269	53183336
Multiple sclerosis relapse	14.64	11.64	13	51448	44840	53252765
Pregnancy	14.61	11.64	6	51455	31435	53266170
Blood pressure fluctuation	14.60	11.64	8	51453	35462	53262143
Cardiac failure	14.46	11.64	39	51422	85805	53211800
Dyssomnia	14.32	11.64	4	51457	39	53297566
Streptococcal bacteraemia	14.26	11.64	12	51449	1572	53296033
Stomatitis	14.19	11.64	151	51310	98007	53199598
Lymphocyte count decreased	14.06	11.64	59	51402	27993	53269612
Neutropenic sepsis	13.73	11.64	38	51423	14611	53282994
Oesophagitis	13.68	11.64	38	51423	14639	53282966
Chills	13.66	11.64	158	51303	104690	53192915
Dizziness	13.62	11.64	462	50999	371797	52925808
Enteritis	13.37	11.64	25	51436	7421	53290184
Lymph node pain	13.29	11.64	11	51450	1409	53296196
Drug abuse	13.25	11.64	27	51434	65499	53232106
Embolism	13.23	11.64	25	51436	7478	53290127
Intentional self-injury	13.16	11.64	4	51457	25280	53272325
Acute myeloid leukaemia	13.08	11.64	41	51420	16891	53280714
Hypersensitivity	13.05	11.64	135	51326	210530	53087075
Therapeutic response decreased	13.04	11.64	16	51445	47553	53250052
Heart rate decreased	12.94	11.64	10	51451	36937	53260668
Inflammation	12.92	11.64	22	51439	57114	53240491
Diabetes mellitus	12.89	11.64	20	51441	53879	53243726
Abdominal discomfort	12.75	11.64	144	51317	220918	53076687
Plasmacytoma	12.67	11.64	14	51447	2567	53295038
Haematocrit decreased	12.55	11.64	70	51391	37261	53260344
Osteonecrosis	12.47	11.64	5	51456	26570	53271035
Hypomagnesaemia	12.29	11.64	52	51409	24759	53272846
Enterocolitis infectious	12.15	11.64	11	51450	1589	53296016
Intentional product misuse	12.13	11.64	18	51443	49374	53248231
Urinary tract infection	12.11	11.64	310	51151	239593	53058012
Wrong technique in product usage process	11.92	11.64	25	51436	60007	53237598
Product quality issue	11.77	11.64	11	51450	37012	53260593
Ascites	11.73	11.64	72	51389	39663	53257942
Cataract	11.69	11.64	85	51376	49535	53248070

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	319.02	12.59	495	32978	119071	32360982
Nausea	235.05	12.59	793	32680	320056	32159997
Fatigue	177.53	12.59	771	32702	349930	32130123
Disease progression	137.68	12.59	287	33186	86575	32393478
Plasma cell myeloma	125.45	12.59	218	33255	57396	32422657
Dehydration	122.75	12.59	350	33123	128608	32351445
Malignant neoplasm progression	97.02	12.59	235	33238	78261	32401792
Diarrhoea	93.53	12.59	668	32805	364134	32115919
Vomiting	93.16	12.59	483	32990	235074	32244979
Death	92.68	12.59	691	32782	381826	32098227
Pneumonia	87.28	12.59	644	32829	354608	32125445
Decreased appetite	79.60	12.59	352	33121	160461	32319592
Drug interaction	68.80	12.59	74	33399	218111	32261942
White blood cell count decreased	64.92	12.59	224	33249	90974	32389079
Drug abuse	63.68	12.59	5	33468	80238	32399815
Toxicity to various agents	58.79	12.59	58	33415	177983	32302070
Neuropathy peripheral	58.23	12.59	193	33280	76789	32403264
Full blood count decreased	56.09	12.59	78	33395	16932	32463121
Drug ineffective	53.38	12.59	209	33264	383268	32096785
Constipation	53.19	12.59	264	33209	126109	32353944
Platelet count decreased	50.80	12.59	243	33230	114348	32365705
Condition aggravated	48.78	12.59	53	33420	155608	32324445
Neutropenia	43.78	12.59	273	33200	141902	32338151
Completed suicide	41.09	12.59	22	33451	92495	32387558
Small intestinal obstruction	39.38	12.59	60	33413	14136	32465917
Overdose	38.24	12.59	21	33452	87056	32392997
Neutrophil count decreased	38.16	12.59	121	33352	47018	32433035
Failure to thrive	37.74	12.59	45	33428	8390	32471663
Cytokine release syndrome	37.26	12.59	57	33416	13478	32466575
Neoplasm progression	37.14	12.59	70	33403	19588	32460465
Hospice care	37.06	12.59	36	33437	5323	32474730
Rash	36.99	12.59	353	33120	208980	32271073
Back pain	33.38	12.59	212	33261	110841	32369212
Psoriasis	31.26	12.59	5	33468	46118	32433935
Deep vein thrombosis	30.31	12.59	138	33335	63575	32416478
Muscle spasms	30.21	12.59	148	33325	70270	32409783
Asthenia	30.14	12.59	373	33100	235571	32244482
Therapeutic product effect incomplete	29.13	12.59	4	33469	41337	32438716
Intentional overdose	27.11	12.59	5	33468	41596	32438457
Product use in unapproved indication	26.95	12.59	30	33443	87174	32392879
Sepsis	26.13	12.59	264	33209	158570	32321483
Rheumatoid arthritis	25.72	12.59	7	33466	44537	32435516
Thrombosis	25.52	12.59	104	33369	45650	32434403
Adverse drug reaction	25.30	12.59	71	33402	25790	32454263
Bradycardia	25.12	12.59	22	33451	71540	32408513
Rhabdomyolysis	24.45	12.59	20	33453	67245	32412808
Ageusia	24.13	12.59	39	33434	9663	32470390
Pulmonary embolism	24.07	12.59	158	33315	83501	32396552
Suicide attempt	24.07	12.59	5	33468	38239	32441814
Coma	24.04	12.59	7	33466	42605	32437448
General physical health deterioration	23.83	12.59	52	33421	115207	32364846
Laboratory test abnormal	23.37	12.59	57	33416	19030	32461023
Cardiac failure	22.78	12.59	37	33436	91636	32388417
Intentional product misuse	22.11	12.59	5	33468	36046	32444007
Spinal cord compression	21.42	12.59	23	33450	3826	32476227
Wrong technique in product usage process	21.23	12.59	5	33468	35054	32444999
Oral pain	20.70	12.59	37	33436	9941	32470112
Coronary artery disease	20.38	12.59	13	33460	49693	32430360
Dysgeusia	20.16	12.59	65	33408	25466	32454587
Off label use	20.14	12.59	210	33263	306110	32173943
Hyponatraemia	19.80	12.59	138	33335	74375	32405678
Injection site pain	19.46	12.59	5	33468	33053	32447000
C-reactive protein increased	19.15	12.59	13	33460	48089	32431964
Drug reaction with eosinophilia and systemic symptoms	18.95	12.59	5	33468	32480	32447573
Hiccups	18.39	12.59	35	33438	9860	32470193
Weight decreased	17.85	12.59	253	33220	164565	32315488
Hypophagia	16.75	12.59	58	33415	23565	32456488
Mental status changes	16.73	12.59	81	33392	38256	32441797
Treatment failure	16.39	12.59	10	33463	39153	32440900
Diaphragmatic rupture	16.37	12.59	4	33469	20	32480033
Plasma cell myeloma recurrent	16.23	12.59	20	33453	3857	32476196
Bacteraemia	15.88	12.59	47	33426	17586	32462467
Pleural effusion	15.82	12.59	137	33336	78855	32401198
Immune effector cell-associated neurotoxicity syndrome	15.74	12.59	13	33460	1555	32478498
Bacillus bacteraemia	15.37	12.59	5	33468	79	32479974
Foetal exposure during pregnancy	15.35	12.59	12	33461	41289	32438764
Oesophagitis	15.08	12.59	38	33435	12943	32467110
Inappropriate schedule of product administration	15.01	12.59	15	33458	45810	32434243
Asthma	14.92	12.59	14	33459	44051	32436002
Clostridium difficile infection	14.68	12.59	46	33427	17750	32462303
Mixed dementia	14.62	12.59	7	33466	318	32479735
Inferior vena caval occlusion	14.45	12.59	4	33469	35	32480018
Dystonia	14.39	12.59	33	33440	10590	32469463
Tooth disorder	14.36	12.59	32	33441	10075	32469978
Cholestasis	14.26	12.59	5	33468	27028	32453025
Temperature intolerance	14.13	12.59	17	33456	3198	32476855
Hypoxia	14.11	12.59	97	33376	52035	32428018
Wrist deformity	14.07	12.59	7	33466	346	32479707
Haematochezia	13.82	12.59	12	33461	39196	32440857
Enterocolitis infectious	13.75	12.59	11	33462	1257	32478796
Seizure	13.48	12.59	58	33415	103796	32376257
Mucosal inflammation	13.43	12.59	69	33404	33365	32446688
Pneumonitis	13.39	12.59	64	33409	30070	32449983
Myocardial infarction	12.99	12.59	76	33397	125600	32354453
Drug dependence	12.99	12.59	4	33469	23480	32456573
Electrocardiogram QT prolonged	12.95	12.59	13	33460	39628	32440425
Cholangiocarcinoma	12.94	12.59	10	33463	1087	32478966
Anaemia	12.85	12.59	311	33162	223313	32256740
Meconium abnormal	12.82	12.59	3	33470	12	32480041
Pancytopenia	12.81	12.59	147	33326	91088	32388965
Oral candidiasis	12.73	12.59	34	33439	11993	32468060
Respiratory arrest	12.64	12.59	7	33466	28901	32451152

Pharmacologic Action:

Source	Code	Description
ATC	N05AB04	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure
FDA CS	M0016525	Phenothiazines
MeSH PA	D000932	Antiemetics
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37890	alpha-adrenoceptor antagonists
CHEBI has role	CHEBI:48561	dopamine blocker
CHEBI has role	CHEBI:48873	Anticholinergika
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:65190	typical antipsychotic drug
CHEBI has role	CHEBI:76779	prolyl oligopeptidase (EC 3.4.21.26) inhibitor
CHEBI has role	CHEBI:131787	D2 receptor antagonist
FDA EPC	N0000175746	Phenothiazine

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Schizophrenia	indication	58214004	DOID:5419
Nonpsychotic Anxiety	indication
Prolonged-Severe Nausea and Vomiting	indication
Migraine	off-label use	37796009	DOID:6364
Chemotherapy-induced nausea and vomiting	off-label use	236084000
Brain damage	contraindication	2470005
Tachyarrhythmia	contraindication	6285003
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Severe chronic ulcerative colitis	contraindication	14311001
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Toxic megacolon	contraindication	28536002	DOID:1770
Orthostatic hypotension	contraindication	28651003
Atony of colon	contraindication	29479008
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Ulcerative colitis	contraindication	64766004	DOID:8577
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Extrapyramidal disease	contraindication	76349003
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Hyperglycemia	contraindication	80394007	DOID:4195
Hiatal hernia	contraindication	84089009	DOID:12642
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Acute disease of cardiovascular system	contraindication	128487001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Angina pectoris	contraindication	194828000
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Visual impairment	contraindication	397540003
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.74	Basic
pKa2	4.74	Basic
pKa3	2.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.76	WOMBAT-PK	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	Ki	8.61	WOMBAT-PK	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.20	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.64	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.82	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.21	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.40	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.23	PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.82	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.19	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.91	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.91	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.62	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	8.32	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	7.72	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.61	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.96	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.49	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.72	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.80	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.92	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.86	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.52	DRUG MATRIX
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7.17	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.89	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.70	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.25	DRUG MATRIX
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.30	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.11	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.31	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.92	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.38	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.49	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.02	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_CAVPO		Ki	6.71	DRUG MATRIX
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.77	CHEMBL

External reference:

ID	Source
4018001	VUID
N0000146346	NUI
D00479	KEGG_DRUG
84-02-6	SECONDARY_CAS_RN
4017999	VANDF
4018000	VANDF
4018001	VANDF
C0033229	UMLSCUI
CHEBI:8435	CHEBI
P77	PDB_CHEM_ID
CHEMBL728	ChEMBL_ID
CHEMBL1200587	ChEMBL_ID
CHEMBL1314751	ChEMBL_ID
DB00433	DRUGBANK_ID
CHEMBL1201154	ChEMBL_ID
D011346	MESH_DESCRIPTOR_UI
4917	PUBCHEM_CID
7279	IUPHAR_LIGAND_ID
699	INN_ID
YHP6YLT61T	UNII
235739	RXNORM
2073	MMSL
5361	MMSL
5362	MMSL
5363	MMSL
6416	MMSL
6417	MMSL
d00355	MMSL
001478	NDDF
001479	NDDF
001480	NDDF
003466	NDDF
22827004	SNOMEDCT_US
372853006	SNOMEDCT_US
3823007	SNOMEDCT_US
395843006	SNOMEDCT_US
79129001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5105	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5110	TABLET, FILM COATED	10 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	0440-8190	TABLET	5 mg	ORAL	ANDA	12 sections
Compro	HUMAN PRESCRIPTION DRUG LABEL	1	0574-7226	SUPPOSITORY	25 mg	RECTAL	ANDA	19 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6135	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0135	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0351	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5020	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5021	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-281	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-511	TABLET	5 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-700	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
PROCHLORPERAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-327	TABLET	10 mg	ORAL	ANDA	10 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-571	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-572	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-294	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-497	INJECTION	5 mg	INTRAMUSCULAR	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-523	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	25021-790	INJECTION	5 mg	INTRAVENOUS	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-141	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-550	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-728	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-729	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	42708-103	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	43063-353	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-742	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	43066-090	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0109	TABLET, FILM COATED	5 mg	ORAL	ANDA	15 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0110	TABLET, FILM COATED	5 mg	ORAL	ANDA	15 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0636	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections